Vimarsana
Biggest News Aggregation in the World

Pharma Outlook News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Outlook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Outlook Today - Breaking & Trending Today

Sun Pharma to buy remaining stake in Taro Pharma for $347.8 million - Vimarsana News

Sun Pharma to buy remaining stake in Taro Pharma for $347.8 million

Sun Pharmaceutical Industries plans to acquire all outstanding shares of Taro Pharmaceutical Industries for $43 per share in cash, aiming to gain complete control over its subsidiary

Q3 result preview: IT firms expected to post muted revenue, subdued profit - Vimarsana News

Q3 result preview: IT firms expected to post muted revenue, subdued profit

Indian IT services companies are expected to report subdued numbers for the December quarter due to weakness in IT services demand and high furloughs.

Nifty Pharma hits all-time high; 10 stocks including Lupin, Cipla, Glenmark Pharma, Divi's Labs touch one-year peaks - Vimarsana News

Nifty Pharma hits all-time high; 10 stocks including Lupin, Cipla, Glenmark Pharma, Divi's Labs touch one-year peaks

In today's trade, Lupin's shares soared nearly 7%, hitting a new all-time high of ₹1,404 apiece after Japanese brokerage firm Nomura raised the target price on the stock to ₹1,593 apiece from the previous ₹1,290, maintaining its 'buy' recommendation.

DGCA issues 1,622 commercial pilot licences in 2023, highest in a decade - Vimarsana News

DGCA issues 1,622 commercial pilot licences in 2023, highest in a decade

The number of Commercial Pilot Licences (CPLs) issued by the Directorate General of Civil Aviation (DGCA) jumped 39% year-on-year to 1,622 in 2023, with women's share going up 22.5%, an official release said on Monday.

The 2024 Outlook For Global Pharma: A Look Ahead - Vimarsana News

The 2024 Outlook For Global Pharma: A Look Ahead

The industry must brace for further pushback from lawmakers, regulators, and other stakeholders who, emboldened by the IRA victory, continue to try to rein in big pharma.

Source: forbes.com